Is a Patented Strain of Bacillus coagulans Probiotic a Viable Adjunct Therapy for Relieving Symptoms of Rheumatoid Arthritis?

A Randomized, Double-Blind, Placebo-Controlled Study of Bacillus coagulans as Adjunct Therapy for the Relief of Symptoms of Rheumatoid Arthritis

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000435280

Enrollment

Registered

2009-06-11

Start date

2005-06-23

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Certain probiotics have demonstrated the ability to lessen the symptoms of arthritis in animals and humans. This clinical trial was conducted to evaluate the effects of the probiotic Bacillus coagulan GBI-30, 6086 on symptoms and functional capacity in patients with rheumatoid arthritis when taken in combination with pharmacological anti-arthritic medications.

Interventions

A patented strain of Bacillus coagulans probiotic in caplet form taken orally with water once daily for 60 days. Each caplet/dose contains 2 x 10 9 colony-forming units (CFUs).

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

36 Years to 82 Years

Healthy volunteers

Inclusion criteria

Subjects were diagnosed with rheumatoid arthritis at least a year prior to the study

Exclusion criteria

Pregnancy, chronic inflammatory bowel disease, kidney or liver disease, and subjects taking >10 mg/day of prednislone or other probiotic products

Outcome results